• Qiagen completed FDA listing in the U.S. for QIAsymphony Connect, its IVD-compliant automated clinical nucleic acid extraction platform.
• Europe EUDAMED listing was also completed, clearing key regulatory steps for broader commercial rollout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 202608271605BIZWIRE_USPR_____20260827_BW453017) on August 27, 2026, and is solely responsible for the information contained therein.